A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)

A Double-Blind, Randomized, Placebo-Controlled, Single-Dose, 3-Period, 4 Treatment Incomplete Crossover Study to Assess the Effects of Single Oral Doses of L-001241689 on Glucagon-Induced Glycemic Excursion in Healthy Male Subjects Following Intravenous Administration of Glucagon, Sandostatine® and Insulin

This is a study to assess the pharmacokinetics, safety, and tolerability of sequential single oral doses of MK-8093 10 mg, 40 mg, 200 mg, or placebo to MK-8093 (Part 1) depending on treatment assignment in young healthy male participants. In Part 2 of this study, sequential single oral doses of MK-8093 200 mg, 1000 mg or placebo to MK-8093 depending on treatment assignment will be evaluated. The primary hypothesis of the study is that at least one dose of MK-0893 will produce greater reduction of glucagon-induced glycemia as compared to placebo following the infusion of glucagon, Sandostatine®, and basal insulin.

Inclusion Criteria:

• Good health
• Body Mass Index of between 18 and 28 kg/m^2, or up to 30 kg/m^2 with approval of sponsor
• Non-smoker for at least 6 months
• Willing to avoid strenuous physical activity
• Willing to avoid alcohol, caffeine, and grapefruit juice consumption

Exclusion Criteria:

• History of renal, neurologic, gastrointestinal or respiratory disease or any gastrointestinal surgery
• History of multiple and/or severe allergies to a prescription, nonprescription or investigational drug or food
• History of any cardiovascular/cardiac disease
• History of any hepatic disease and primary biliary cirrhosis
• History of hypoglycemia or glucose intolerance, type 1 diabetes, or type 2 diabetes
• Requires or anticipates use of prescription or nonprescription medications, including herbal remedies
• A user of any illicit drugs or a history of drug or alcohol abuse
• Surgery, donated a unit of blood, or participated in another clinical study within 4 weeks prior to study participation
• History of hypersensitivity to insulin, glucagon, or Sandostatine®.